Company: WHWK
Filing Date: 2025-01-21
Form Type: PREM14A
Source: 0001193125-25-009599
Chunk: 57

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-21
Form: PREM14A
Chunk 57
---
 entity of competent jurisdiction, in each case that has been entered or enacted that prevents or materially impairs the consummation of the Divestiture. Accordingly, if litigation is or
enacted filed challenging the Divestiture and a plaintiff is successful in obtaining an order enjoining completion of the Divestiture, then such order may prevent the Divestiture from being completed at all or from being completed within the
expected time frame.

Risks Related to the PIPE Financing

Our stockholders will experience significant dilution as a result of the PIPE Financing if the PIPE Financing Proposal is approved at the Special Meeting. The number of shares we have agreed to sell in the PIPE Financing is significant in relation to the number of outstanding shares of our common stock.

Our stockholders will experience significant dilution as a result of the PIPE Financing if the PIPE Financing Proposal is approved at the Special Meeting.
Pursuant to the Subscription Agreement and the terms of the PIPE Financing, we have agreed to issue and sell to the PIPE Investors (i) 21,592,000 shares of our common stock and (ii) 20,076,500 Pre-Funded Warrants to acquire common stock, subject to
stockholder approval at the Special Meeting. If the PIPE Financing Proposal is approved and the PIPE Offering is completed, we will have 46,272,708 outstanding shares of common stock and an additional 20,076,500 Pre-Funded Warrants outstanding.

- 38 -

After the closing of the PIPE Financing, the shares of common stock issued to the PIPE Investors will account for approximately 47% of the total shares outstanding (based on 24,680,708 total
shares outstanding as of December 31, 2024 and after giving effect to the 21,592,000 shares expected to be issued in the PIPE Financing). If the PIPE Investors exercise all 20,076,500 Pre-Funded Warrants issued in the PIPE Financing, the securities
issued in the PIPE Financing will account for approximately 63% of the total shares outstanding at that time (based on 24,680,708 total shares outstanding as of December 31, 2024 and after giving effect to the 21,592,000 shares expected to be
issued in the PIPE Financing and 20,076,500 shares that would be issued pursuant to exercise of the Pre-Funded Warrants).As a result, stockholders who did not participate in the PIPE Financing will experience substantial dilution upon
closing of the PIPE Financing, if approved